Efficacy Safety and Tolerability of Atogepant for the Prevention of Chronic Migraine

  • End date
    Feb 11, 2022
  • participants needed
  • sponsor
Updated on 24 July 2021


This study will evaluate the efficacy, safety and tolerability of atogepant in participants with chronic migraine. This study includes a 12-week treatment period.

Condition Chronic Migraine
Treatment Placebo, Atogepant 60 mg, Atogepant 30 mg
Clinical Study IdentifierNCT03855137
Last Modified on24 July 2021


Yes No Not Sure

Inclusion Criteria

At least a 1-year history of CM consistent with a diagnosis according to the ICHD-3, 2018
Age of the participant at the time of migraine onset < 50 years
Confirmation of headache/migraine headache day frequency as follows
History of, on average, 15 headache days per month in the 3 months prior to Visit 1 in the opinion of the investigator AND
headache days during the 4-week screening/baseline period per the electronic diary (eDiary) AND
days during the 4-week screening/baseline period that qualify as being a migraine day per the eDiary
Participants must be using a medically acceptable and effective method of birth control during the course of the entire study

Exclusion Criteria

Has a history of migraine, accompanied by diplopia or decreased level of consciousness, or retinal migraine
Has a current diagnosis of new persistent daily headache, trigeminal autonomic cephalgia (eg, cluster headache), or painful cranial neuropathy
History of an inadequate response to > 4 medications (2 of which have different mechanisms of action) prescribed for the prevention of migraine
Woman is pregnant, planning to become pregnant during the course of the study, or currently lactating. Women of childbearing potential must have a negative urine pregnancy test at Visit 1 and Visit 2
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note